PMID- 26408528
OWN - NLM
STAT- MEDLINE
DCOM- 20160504
LR  - 20181113
IS  - 1521-0081 (Electronic)
IS  - 0031-6997 (Print)
IS  - 0031-6997 (Linking)
VI  - 67
IP  - 4
DP  - 2015 Oct
TI  - Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological 
      Targets and Implications for Disease.
PG  - 1005-24
LID - 10.1124/pr.114.010397 [doi]
AB  - Dopamine (DA) plays a well recognized role in a variety of physiologic functions 
      such as movement, cognition, mood, and reward. Consequently, many human disorders 
      are due, in part, to dysfunctional dopaminergic systems, including Parkinson's 
      disease, attention deficit hyperactivity disorder, and substance abuse. Drugs 
      that modify the DA system are clinically effective in treating symptoms of these 
      diseases or are involved in their manifestation, implicating DA in their 
      etiology. DA signaling and distribution are primarily modulated by the DA 
      transporter (DAT) and by vesicular monoamine transporter (VMAT)-2, which 
      transport DA into presynaptic terminals and synaptic vesicles, respectively. 
      These transporters are regulated by complex processes such as phosphorylation, 
      protein-protein interactions, and changes in intracellular localization. This 
      review provides an overview of 1) the current understanding of DAT and VMAT2 
      neurobiology, including discussion of studies ranging from those conducted in 
      vitro to those involving human subjects; 2) the role of these transporters in 
      disease and how these transporters are affected by disease; and 3) and how 
      selected drugs alter the function and expression of these transporters. 
      Understanding the regulatory processes and the pathologic consequences of DAT and 
      VMAT2 dysfunction underlies the evolution of therapeutic development for the 
      treatment of DA-related disorders.
CI  - Copyright (c) 2015 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - German, Christopher L
AU  - German CL
AD  - School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of 
      Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, 
      Utah.
FAU - Baladi, Michelle G
AU  - Baladi MG
AD  - School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of 
      Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, 
      Utah.
FAU - McFadden, Lisa M
AU  - McFadden LM
AD  - School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of 
      Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, 
      Utah.
FAU - Hanson, Glen R
AU  - Hanson GR
AD  - School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of 
      Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, 
      Utah.
FAU - Fleckenstein, Annette E
AU  - Fleckenstein AE
AD  - School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of 
      Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, 
      Utah fleckenstein@hsc.utah.edu.
LA  - eng
GR  - R01 DA011389/DA/NIDA NIH HHS/United States
GR  - K99-DA036012/DA/NIDA NIH HHS/United States
GR  - P01 DA013367/DA/NIDA NIH HHS/United States
GR  - R01-DA11389/DA/NIDA NIH HHS/United States
GR  - K99 DA036012/DA/NIDA NIH HHS/United States
GR  - K02-DA019447/DA/NIDA NIH HHS/United States
GR  - P01-DA13367/DA/NIDA NIH HHS/United States
GR  - R01-DA031883/DA/NIDA NIH HHS/United States
GR  - K02 DA019447/DA/NIDA NIH HHS/United States
GR  - R01 DA031883/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Pharmacol Rev
JT  - Pharmacological reviews
JID - 0421737
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Dopamine Agents)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/pharmacology
MH  - Animals
MH  - Central Nervous System Diseases/physiopathology
MH  - Dopamine/*metabolism
MH  - Dopamine Agents/pharmacology
MH  - Dopamine Plasma Membrane Transport Proteins/*pharmacology/*physiology
MH  - Glycosylation
MH  - Humans
MH  - Phosphorylation/physiology
MH  - Signal Transduction
MH  - Synaptic Transmission
MH  - Vesicular Monoamine Transport Proteins/classification/*pharmacology/*physiology
PMC - PMC4630566
EDAT- 2015/09/27 06:00
MHDA- 2016/05/05 06:00
PMCR- 2016/10/01
CRDT- 2015/09/27 06:00
PHST- 2015/09/27 06:00 [entrez]
PHST- 2015/09/27 06:00 [pubmed]
PHST- 2016/05/05 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - 67/4/1005 [pii]
AID - PHARMREV_010397 [pii]
AID - 10.1124/pr.114.010397 [doi]
PST - ppublish
SO  - Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397.